Carcinoma

Understand Why Only 25% of the Global Renal Cell Carcinoma Market Is In Europe

Published in Cancer Weekly, September 25th, 2007

Research and Markets has announced the addition of "Cancer Drug Discoveries: What the Future Holds: Renal Cancer Chapter" to their offering.

The renal cell carcinoma (RCC) market was estimated to be worth around US$1 billion in 2006, with a growth rate of 36% YoY. It has constituted a relatively small segment of the oncology market but has more recently attracted considerable research and development investment from big pharmaceutical, biotechnology and specialty pharma companies.

The market is currently driven by the use of the following immunomodulating agents: Schering-Plough's Intron A...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry